Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Chief Financial Officer of Bicara Therapeutics Inc (NASDAQ:BCAX), Hyep Ivan, sold a total of 30,385 shares of common stock between October 6th and October 8th, 2025. The sales were executed at weighted average prices ranging from $18.1695 to $18.2189, resulting in total proceeds of approximately $553,198. The transaction comes amid a strong performance period for BCAX, with the stock recording a 94% gain over the past six months and a 9% rise in the past week.
On the same dates, Hyep Ivan also exercised options to acquire a total of 30,385 shares of Bicara Therapeutics common stock at a price of $3.7898 per share, for a total value of $115153. According to InvestingPro analysis, the stock currently trades slightly above its Fair Value, with analyst price targets ranging from $8 to $48 per share.
Following these transactions, Hyep Ivan directly owns 145,355 shares of Bicara Therapeutics Inc. The company maintains strong liquidity with a current ratio of 25.8, and InvestingPro data shows 12 additional key insights available for subscribers.
In other recent news, Bicara Therapeutics has seen a series of analyst actions and developments. TD Cowen reiterated its Buy rating for Bicara Therapeutics, highlighting the $8 billion acquisition of Merus by Genmab as a positive indicator for the field of EGFR bispecific antibodies, where Bicara is also active. Jones Trading initiated coverage on Bicara with a Buy rating and a $22 price target, noting the promising clinical data from its bispecific antibody treatment for head and neck cancer. H.C. Wainwright maintained its Buy rating but slightly lowered its price target to $40, citing projected higher long-term operating expenses. Piper Sandler also initiated coverage with an Overweight rating and a $36 price target, emphasizing a disconnect between market perception and expert opinions on Bicara’s ficera treatment. Meanwhile, Rice Biotech Launch Pad, an accelerator based in Houston, announced the addition of Carolyn Ng from TPG Life Sciences to its external advisory board, highlighting its commitment to advancing health and medical technology discoveries. These developments reflect ongoing interest and activity surrounding Bicara Therapeutics in the investment community.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.